Codiak Biosciences Inc. (CDAK) PT Raised to 'Street High' $31 at Wedbush Following Data

Go back to Codiak Biosciences Inc. (CDAK) PT Raised to 'Street High' $31 at Wedbush Following Data

Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers

December 30, 2020 7:00 AM EST

exoIL-12 resulted in no local or systemic treatment-related adverse events

Local administration of exoIL-12 demonstrated no systemic exposure to IL-12

Dose selection data and advancement into multi-dose study in cutaneous T cell lymphoma patients anticipated in Q1 2021

CAMBRIDGE, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that the primary objectives were met in the initial part of its Phase 1 trial, which evaluated a single ascending dose of... More